Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models

Triple negative breast cancer (TNBC) accounts for over 30% of all breast cancer (BC)-related deaths, despite accounting for only 10% to 15% of total BC cases. Targeted therapy development has largely stalled in TNBC, underlined by a lack of traditionally druggable addictions like receptor tyrosine k...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Jacob, Sheeba, Turner, Tia H, Cai, Jinyang, Floros, Konstantinos V, Yu, Ann K, Coon, Colin M, Khatri, Rishabh, Alzubi, Mohammad A, Jakubik, Charles T, Bouck, Ynes M, Puchalapalli, Madhavi, Shende, Mayuri, Dozmorov, Mikhail G, Boikos, Sosipatros A, Hu, Bin, Harrell, J Chuck, Benes, Cyril H, Koblinski, Jennifer E, Costa, Carlotta, Faber, Anthony C
التنسيق: Online مقال نص
اللغة:English
منشور في: Oxford University Press 2022
الموضوعات:
Biological, Health, and Medical Sciences
الوصول للمادة أونلاين:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802478/
https://www.ncbi.nlm.nih.gov/pubmed/36712364
http://dx.doi.org/10.1093/pnasnexus/pgac232

الانترنت

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802478/
https://www.ncbi.nlm.nih.gov/pubmed/36712364
http://dx.doi.org/10.1093/pnasnexus/pgac232

مواد مشابهة